SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have achieved a significant milestone with the publication of an international patent application for their novel combination therapy. The therapy combines Clearmind's MEAI with SciSparc's Palmitoylethanolamide (PEA) to target metabolic syndrome and obesity.
The patent application, published under the European Patent Office, represents one of 13 patent families filed across multiple jurisdictions including the US, Europe, and China. The collaboration aims to address conditions affecting up to one-third of U.S. adults, combining PEA's anti-inflammatory properties with MEAI's pharmacological profile to treat metabolic disorders, mental health conditions, and addictions.
SciSparc (Nasdaq: SPRC) e Clearmind Medicine hanno raggiunto un traguardo importante con la pubblicazione di una domanda di brevetto internazionale per la loro nuova terapia combinata. La terapia unisce il MEAI di Clearmind con la Palmitoiletanolamide (PEA) di SciSparc per contrastare la sindrome metabolica e l'obesità.
La domanda di brevetto, pubblicata dall'Ufficio Brevetti Europeo, fa parte di 13 famiglie di brevetti depositate in diverse giurisdizioni, tra cui Stati Uniti, Europa e Cina. La collaborazione punta a trattare condizioni che riguardano fino a un terzo degli adulti statunitensi, combinando le proprietà anti-infiammatorie della PEA con il profilo farmacologico del MEAI per curare disturbi metabolici, condizioni di salute mentale e dipendenze.
SciSparc (Nasdaq: SPRC) y Clearmind Medicine han alcanzado un hito significativo con la publicación de una solicitud de patente internacional para su novedosa terapia combinada. La terapia combina el MEAI de Clearmind con el Palmitoiletanolamida (PEA) de SciSparc para abordar el síndrome metabólico y la obesidad.
La solicitud de patente, publicada por la Oficina Europea de Patentes, representa una de las 13 familias de patentes presentadas en varias jurisdicciones, incluyendo EE.UU., Europa y China. La colaboración tiene como objetivo tratar condiciones que afectan hasta a un tercio de los adultos en EE.UU., combinando las propiedades antiinflamatorias de la PEA con el perfil farmacológico del MEAI para tratar trastornos metabólicos, condiciones de salud mental y adicciones.
SciSparc (나스닥: SPRC)와 Clearmind Medicine은 새로운 복합 치료법에 대한 국제 특허 출원 발표로 중요한 이정표를 달성했습니다. 이 치료법은 Clearmind의 MEAI와 SciSparc의 팔미토일에탄올아마이드(PEA)를 결합하여 대사 증후군과 비만을 목표로 합니다.
유럽 특허청에 등록된 이 특허 출원은 미국, 유럽, 중국 등 여러 관할구역에 제출된 13개의 특허 패밀리 중 하나입니다. 이 협력은 미국 성인 3분의 1에 영향을 미치는 상태를 다루는 것을 목표로 하며, PEA의 항염증 특성과 MEAI의 약리학적 특성을 결합하여 대사 장애, 정신 건강 문제 및 중독을 치료합니다.
SciSparc (Nasdaq : SPRC) et Clearmind Medicine ont franchi une étape importante avec la publication d'une demande de brevet internationale pour leur nouvelle thérapie combinée. Cette thérapie associe le MEAI de Clearmind au Palmitoyléthanolamide (PEA) de SciSparc pour cibler le syndrome métabolique et l'obésité.
La demande de brevet, publiée par l'Office européen des brevets, fait partie de 13 familles de brevets déposées dans plusieurs juridictions, dont les États-Unis, l'Europe et la Chine. Cette collaboration vise à traiter des affections touchant jusqu'à un tiers des adultes américains, en combinant les propriétés anti-inflammatoires de la PEA avec le profil pharmacologique du MEAI pour soigner les troubles métaboliques, les problèmes de santé mentale et les addictions.
SciSparc (Nasdaq: SPRC) und Clearmind Medicine haben einen bedeutenden Meilenstein erreicht mit der Veröffentlichung einer internationalen Patentanmeldung für ihre neuartige Kombinationstherapie. Die Therapie kombiniert Clearminds MEAI mit SciSparcs Palmitoylethanolamid (PEA), um das metabolische Syndrom und Fettleibigkeit zu behandeln.
Die Patentanmeldung, veröffentlicht beim Europäischen Patentamt, ist Teil von 13 Patentfamilien, die in verschiedenen Rechtsgebieten wie den USA, Europa und China eingereicht wurden. Die Zusammenarbeit zielt darauf ab, Erkrankungen zu behandeln, die bis zu betreffen, indem die entzündungshemmenden Eigenschaften von PEA mit dem pharmakologischen Profil von MEAI kombiniert werden, um Stoffwechselstörungen, psychische Erkrankungen und Abhängigkeiten zu behandeln.
- Publication of international patent application strengthens intellectual property portfolio
- Extensive patent protection across 13 patent families in major markets (US, Europe, China)
- Addresses large market opportunity with one-third of US adults affected by metabolic syndrome
- Novel combination therapy leverages complementary properties of both compounds
- Early-stage development with no clinical data presented
- Competitive market for metabolic syndrome and obesity treatments
Insights
SciSparc-Clearmind patent application for obesity treatment represents valuable IP development, though commercialization remains distant with significant regulatory hurdles ahead.
The publication of an international PCT patent application covering the MEAI-PEA combination therapy marks a significant milestone in SciSparc's intellectual property portfolio. This development strengthens the company's competitive positioning in the lucrative metabolic syndrome and obesity markets, which affect approximately one-third of U.S. adults.
The patent strategy appears robust, with applications filed across major markets including the US, Europe, and China. This comprehensive approach to IP protection is particularly important for clinical-stage pharmaceutical companies, as strong patents can become valuable assets for future licensing deals or partnerships.
However, investors should understand the distinction between patent publication and patent grant. Publication simply means the application is now public; it doesn't guarantee approval or confer enforceable rights. The PCT process typically serves as a preliminary step before entering national phases where actual patents may be granted.
The science behind the combination is intriguing - pairing PEA's anti-inflammatory properties with MEAI's unique pharmacological profile could potentially address multiple aspects of metabolic syndrome simultaneously. That said, the company is still in clinical-stage development, meaning significant regulatory hurdles remain before commercialization.
This patent publication represents just one component of a broader collaboration that has generated 13 patent families addressing mental health disorders, addictions, and metabolic conditions - demonstrating a diversified approach to CNS therapeutics that could mitigate risk through multiple potential revenue streams.
TEL AVIV, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the publication of an international patent application under the Patent Cooperation Treaty (PCT).
The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc’s Palmitoylethanolamide (PEA) for the treatment of metabolic syndrome and obesity.
Metabolic syndrome, characterized by conditions such as high blood pressure, high blood sugar, excess abdominal fat, and elevated cholesterol levels. According to Mayo Clinic, this syndrome affects up to one-third of U.S. adults and increases the risk of heart disease, stroke, obesity and type 2 diabetes. This proprietary combination therapy leverages PEA’s anti-inflammatory and neuroprotective properties alongside MEAI’s unique pharmacological profile to offer potential safe and effective treatment for these widespread health challenges.
This patent publication marks a significant milestone in the Clearmind-SciSparc collaboration, which has resulted in the filing of 13 patent families, across multiple jurisdictions, such as the United States, Europe, and China. The collaboration focuses on developing innovative therapies that combine neuroplastogens molecules with N-acylethanolamines, including PEA, to address mental health disorders such as depression and PTSD, addictions, and various metabolic conditions.
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on the Amazon.com Marketplace.
About Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY)
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind’s intellectual portfolio currently consists of 19 patent families including 31 granted patents. For further information visit: https://www.clearmindmedicine.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the new patent application, and that this proprietary combination has the potential to address: obesity and metabolic syndrome. Since such statements deal with future events and are based on SciSparc’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What is the new patent application from SciSparc (SPRC) and Clearmind about?
How many patent families has the SciSparc-Clearmind collaboration generated?
What conditions will SciSparc's (SPRC) new combination therapy target?
What is the market potential for SciSparc's (SPRC) metabolic syndrome treatment?
What are the key compounds in SciSparc's (SPRC) new combination therapy?
